We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current MXC market cap is 9.65M. The company's latest EPS is AUD -0.3998 and P/E is -0.38.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 2.75M | 3.85M | 4.74M | 4.16M | 3.02M |
| Operating Income | -17M | -11.8M | -19.4M | -18.14M | -16.64M |
| Net Income | -19.36M | -15.87M | -20.35M | -20.82M | -17.53M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 7.93M | 24.24M | 18.56M | 9.98M | 10.79M |
| Total Liabilities | 4.84M | 10.41M | 13.38M | 18.02M | 16.61M |
| Total Equity | 3.09M | 13.83M | 5.18M | -8.03M | -5.83M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -9.96M | -11.99M | -12.16M | -11.99M | -14.66M |
| Investing | -970k | -1.49M | -1.11M | 606k | -140k |
| Financing | 10.46M | 17.05M | 9.74M | 9.73M | 15.27M |
| Market Cap | 9.65M |
| Price to Earnings Ratio | -0.38 |
| Price to Sales Ratio | 2.18 |
| Price to Cash Ratio | 9.38 |
| Price to Book Ratio | -1.13 |
| Dividend Yield | - |
| Shares Outstanding | 43.85M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -18.52% |
| 52 Week High | 27.50 |
| 52 Week Low | 17.50 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Mgc Pharmaceuticals Limited |
| Address |
1202 hay street perth, western australia 6005 |
| Website | https://www.mgcpharma.com.au |
| Industry | drug & proprietary stores (5912) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
